12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Opaxio paclitaxel poliglumex: Preliminary Phase II data

Preliminary data from an open-label Phase II trial in 22 evaluable patients with newly-diagnosed high-grade glioma show that once-weekly 50 mg/m 2 Opaxio plus standard of care (SOC) for 6 weeks produced an ORR of 45%, including 6 complete responses and 4 partial responses,...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >